Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000919574-25-000556
Filing Date
2025-01-28
Accepted
2025-01-28 20:07:41
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 15373
2 d1159607_ex-99.htm EX-99 6164
  Complete submission text file 0000919574-25-000556.txt   23521
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Subject) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-42290 | Film No.: 25566296
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address BROADWOOD CAPITAL INC. 156 WEST 56TH STREET, 3RD FLOOR NEW YORK NY 10019
Business Address BROADWOOD CAPITAL INC. 156 WEST 56TH STREET, 3RD FLOOR NEW YORK NY 10019 212-508-5735
BROADWOOD PARTNERS, L.P. (Filed by) CIK: 0001278386 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A